title: Microalbuminuria and sRAGE in high-risk hypertensive patients treated with nifedipine/telmisartan combination treatment: a substudy of TALENT.
abstract: Some antihypertensive drugs have also renoprotective and anti-inflammatory properties that go beyond their effect on blood pressure. It has been suggested that microalbuminuria and glomerular filtration rate (GFR) are associated with circulating levels of the soluble form of the receptor, sRAGE (soluble receptor for advanced glycation ends-products). In the present analysis, we used data from the TALENT study to evaluate soluble receptor for advanced glycation end-products (sRAGE) plasma levels in patients with hypertension and high-cardiovascular risk-treated nifedipine and telmisartan in combination. Treatment with nifedipine-telmisartan significantly decreased mean systolic and diastolic ambulatory blood pressure and resulted in a significant increase in sRAGE plasma concentrations after 24 weeks of therapy. We concluded that in hypertensive patients with early-stage renal disease, sRAGE concentrations are not influenced by either microalbuminuria or GFR. Long-term treatment with a combination of nifedipine-telmisartan may have a beneficial effect increasing sRAGE plasma levels, thus exerting an atheroprotective and anti-inflammatory activity.
authors.affiliation: Interdepartmental Center of Research in Molecular Medicine-CIRMC, University of Pavia, 27100 Pavia, Italy. colomba.falcone@unipv.it
authors.forename: Colomba
authors.initials: C
authors.lastname: Falcone
authors.forename: Maria Paola
authors.initials: MP
authors.lastname: Buzzi
authors.forename: Sara
authors.initials: S
authors.lastname: Bozzini
authors.forename: Chiara
authors.initials: C
authors.lastname: Boiocchi
authors.forename: Angela
authors.initials: A
authors.lastname: D'Angelo
authors.forename: Sandra
authors.initials: S
authors.lastname: Schirinzi
authors.forename: Ciro
authors.initials: C
authors.lastname: Esposito
authors.forename: Massimo
authors.initials: M
authors.lastname: Torreggiani
authors.forename: Jasmine
authors.initials: J
authors.lastname: Choi
authors.forename: Michael
authors.initials: M
authors.lastname: Ochan Kilama
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Mancia
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000419:Albuminuria / Q000097:blood*; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001562:Benzimidazoles / Q000627:therapeutic use*; D001565:Benzoates / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D017127:Glycation End Products, Advanced / Q000097:blood; D006801:Humans; D006973:Hypertension / Q000097:blood* / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009543:Nifedipine / Q000627:therapeutic use*; D000077333:Telmisartan; D055815:Young Adult
chemical_list: D000959:Antihypertensive Agents; D001562:Benzimidazoles; D001565:Benzoates; D004338:Drug Combinations; D017127:Glycation End Products, Advanced; D009543:Nifedipine; D000077333:Telmisartan